2022 News | Solas BioVentures

2022

December 14, 2022

Learn More

Field Medical and CardioNXT Collaborate to Deliver Novel Integration of Focal Pulsed Field Ablation And 3D Mapping & Navigation For Treatment of Cardiac Arrhythmias

December 13, 2022

Learn More

Mark Christopherson Joins Solas BioVentures as Entrepreneur in Residence

December 1, 2022

Learn More

Vesalio appoints VP of U.S. Sales and announces recent publication on NeVa showing impressive first pass rates

November 29, 2022

Learn More

Tvardi Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

November 29, 2022

Learn More

Baebies Receives FDA 510(k) Clearance for G6PD Test on FINDER Platform

November 9, 2022

Learn More

FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma

October 19, 2022

Learn More

Arrivo BioVentures Announces SP-624 Demonstrated Robust Efficacy in Females With Major Depressive Disorder in Phase 2 Study

October 17, 2022

Learn More

Vesalio announces EU MDR Certification

October 13, 2022

Learn More

Vesalio Announces FDA Approval of the NeVa VS™ to Treat Cerebral Vasospasm After Aneurysmal Rupture

September 15, 2022

Learn More

Vesalio announces CE Approval for new NeVa NET™

September 1, 2022

Learn More

Finance Executive David Belitz Joins Solas BioVentures

August 29, 2022

Learn More

Wiedmer: No one has turned tragedy to triumph better than Jordan Thomas

August 10, 2022

Learn More

EirSystems Announces Close of Seed Financing Round to Advance Software for Preventing Prescription Abuse

August 8, 2022

Learn More

Solas BioVentures Presents Servant-Leadership Award to Veterans Entrepreneurship Program Participant, Michael Scott

August 4, 2022

Learn More

Stimdia Medical Announces Close of Series B Equity Financing Round with Proceeds to be Used to Complete the Company’s Pivotal Study

July 14, 2022

Learn More

Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding

July 12, 2022

Learn More

Renovia receives FDA clearance for leva® Pelvic Health System as first-line treatment for chronic fecal incontinence

July 7, 2022

Learn More

Arrivo BioVentures Closes Enrollment in Large Phase 2 Clinical Trial for Major Depressive Disorder

May 26, 2022

Learn More

Vesalio Announces Oversubscribed Class A Financing

May 18, 2022

Learn More

Renovia advances access to first-line treatment for female urinary incontinence with 1,000 leva prescribers

May 17, 2022

Learn More

Vesalio Announces Completion of Enrollment in its FDA Enabling Stroke Study

May 11, 2022

Learn More

Tvardi Therapeutics to Participate in Morgan Stanley Private Company Biotech Corporate Access Day

April 28, 2022

Learn More

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma

April 21, 2022

Learn More

Green Journal publishes study showing leva “significantly improved” symptoms of urinary incontinence in women versus Kegel exercises alone

March 11, 2022

Learn More

Capital Women’s Care to offer leva to patients across 55 locations in Maryland, Virginia, and Washington DC

March 7, 2022

Learn More

Biohaven Acquires Kv7 Ion Channel Platform For The Treatment Of Epilepsy And Other Neurologic Disorders From Channel Biosciences, A Subsidiary Of Knopp Biosciences

February 25, 2022

Learn More

Vesalio Announces Earl Slee as New Board Observer and Senior Advisor to the Company

February 3, 2022

Learn More

Vesalio Announces Appointment of Mike Kujak as its New Independent Board Chairman

January 19, 2022

Learn More

Healthcare Technology Report announces their Top 25 Women Leaders in Medical Devices of 2022

January 14, 2022

Learn More

Renovia receives 2021 Excellence Award for leva

January 6, 2022

Learn More